PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
Immunotherapy can become a crucial therapeutic option to improve prognosis for lung cancer patients. First clinical trials with therapies targeting the programmed cell death receptor PD-1 and its ligand PD-L1 have shown promising results in several solid tumors. However, in lung cancer the diagnosti...
Main Authors: | Lars Henning Schmidt, Andreas Kümmel, Dennis Görlich, Michael Mohr, Sebastian Bröckling, Jan Henrik Mikesch, Inga Grünewald, Alessandro Marra, Anne M Schultheis, Eva Wardelmann, Carsten Müller-Tidow, Tilmann Spieker, Christoph Schliemann, Wolfgang E Berdel, Rainer Wiewrodt, Wolfgang Hartmann |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4552388?pdf=render |
Similar Items
-
State of PD-L1 and PD-1 screening and therapy in NSCLC
by: Frido Bruehl, et al.
Published: (2018-04-01) -
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
by: Mengke Niu, et al.
Published: (2021-03-01) -
Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
by: Melanie Janning, et al.
Published: (2019-06-01) -
Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐PD‐1/PD‐L1 agents?
by: Michal Sternschuss, et al.
Published: (2020-08-01) -
SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges
by: Yu Chen, et al.
Published: (2020-07-01)